查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088909

腦腫瘤診斷市場：2026-2032年全球市場預測（按產品、腫瘤類型、檢體類型、腫瘤分級、臨床應用及最終用戶分類）

Brain Cancer Diagnostics Market by Offering, Tumor Type, Sample Type, Tumor Grade Type, Clinical Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦腫瘤診斷市場將成長至 40.3 億美元，複合年成長率為 10.62%。

主要市場統計數據
基準年 2025 19.9億美元
預計年份：2026年 21.9億美元
預測年份 2032 40.3億美元
複合年成長率 (%) 10.62%

腦腫瘤診斷市場執行摘要

腦腫瘤的診斷正從主要依賴解剖學的方法轉向綜合診斷模式，該模式結合了磁振造影（MRI）、組織病理學、免疫組織化學、分子病理學、次世代定序以及日益重要的液態生物檢體活體組織切片。世界衛生組織（WHO）對中樞神經系統（CNS）腫瘤的分類強調了分子特徵，例如IDH突變狀態、1p/19q共缺失、H3 K27突變、TERT啟動子突變、ATRX缺失和MGMT啟動子甲基化。精準診斷在治療方案選擇、預後判斷以及臨床試驗入組合格方面發揮核心作用。

一場將改變我們診斷方式的改變。

腦腫瘤的診斷方式正受到三大相互關聯的變革的影響：分子分型、數位化工作流程的引入以及對微創監測的需求。儘管傳統磁振造影（MRI）在腫瘤檢測、手術計畫制定和治療反應評估中仍然發揮著至關重要的作用，但先進的MRI技術、特定情況下的胺基酸正子斷層掃描（PET）、灌注成像、波譜分析以及放射科和病理科之間的協作正在不斷提高診斷的準確性。

人工智慧（AI）的累積影響

人工智慧 (AI) 對基於影像的分流、分割、放射組學、病理影像分析、分子預測和臨床決策支援等領域產生了累積的影響。 AI 工具可以幫助實現可重複的腫瘤體積測量、識別細微的影像模式、輔助評估治療反應，並減輕重複性人工工作的負擔。然而，它們的臨床價值取決於外部檢驗、可解釋性、偏差監控以及與放射科醫生和病理科醫生工作流程的整合。

按地區分類的主要發現

北美地區仍然是腦腫瘤診斷領域的領先地區，這得益於其高MRI使用率、分子病理學的廣泛應用、強大的學術癌症中心以及完善的臨床基因組檢測保險報銷機制。儘管美國和加拿大受益於活躍的臨床試驗網路、神經腫瘤學的亞專科化以及基於指南的腫瘤治療，但當地的醫療資源獲取、保險系統的複雜性以及自付費用仍然影響著診斷的公平性。

關鍵群體特定見解

在七國集團（G7）國家，腦腫瘤診斷的廣泛應用得益於成熟的影像基礎設施、專業的神經腫瘤中心、完善的臨床指南以及日益將分子標誌物視為臨床必需手段的保險報銷體系。北約成員國的醫療體系與許多高所得國家的醫療體系重疊，促進了跨境研究合作、醫療數據網路安全需求以及先進診斷平台採購的統一標準。

主要國家的關鍵見解

美國在創新方面處於領先地位，這得益於其完善的癌症中心、規範的診斷技術、廣泛的臨床試驗活動以及對磁振造影和分子分型技術的積極應用。加拿大則強調公共醫療、地方癌症計畫和品質保證的病理網路。同時，墨西哥和巴西正在擴大其腫瘤基礎設施，但面臨公立和私立醫療系統在醫療服務取得方面的差距。在歐洲，英國、德國、法國、義大利和西班牙將基於指南的醫療保健與國家保險報銷審查相結合，建立了完善的神經腫瘤服務體系，並增加了分子分型技術的應用。另一方面，儘管俄羅斯在醫療服務取得方面存在區域差異，但其在都市區仍然保持強大的專科中心。

為行業領導者提供的實用建議

產業領導者應優先考慮可立即整合到工作流程中的、經過臨床檢驗的診斷解決方案，而不是獨立的技術。最大的機會在於建立一個整合平台，該平台能夠連接磁振造影、病理學、基因組檢測、甲基化分析、結構化報告和腫瘤委員會決策支持，同時縮短週轉時間並保留組織樣本用於必要的檢測。

調查方法

本執行摘要基於公開且可驗證的來源，包括世界衛生組織中樞神經系統腫瘤分類原則、國際癌症研究機構/全球癌症研究聯盟（IARC/GLOBOCAN）癌症負擔評估、美國國家癌症研究所數據、同行檢驗的神經腫瘤學文獻、監管指南和經認證的臨床實踐指南。本分析重點在於具有臨床意義的成熟或新型診斷資訊來源，例如磁振造影（MRI）、組織病理學、免疫組織化學、分子譜分析、次世代定序（NGS）、甲基化分析、數位病理學、人工智慧輔助成像和液態生物檢體活體組織切片。

結論

腦腫瘤的診斷已進入精準醫療階段，準確的分類、分子水平的確認以及對觀察的快速多學科主導，直接影響著治療方案的選擇、臨床試驗的合格以及患者諮詢。中樞神經系統（CNS）癌症的沉重負擔以及膠質瘤的生物學複雜性，使得診斷品質成為醫療系統、實驗室、影像服務提供者和技術開發人員的策略重點。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：腦腫瘤診斷市場：依產品/服務分類

  • 裝置
    • 醫療影像設備
      • 磁振造影（MRI）系統
      • 電腦斷層掃描（CT）系統
      • 正子斷層掃描（PET）系統
    • 分子和病理診斷設備
      • 序列器
      • 聚合酵素鏈鎖反應（PCR）系統
      • 微陣列系統
      • 螢光原位雜合反應（FISH）平台
      • 次世代定序（NGS）系統
    • 組織採集器
      • 切片穿刺針
      • 定位框架
      • 神經導航系統
      • 內視鏡取樣裝置
  • 耗材和試劑
    • 診斷成像耗材
      • 造影
      • 放射性示踪劑
      • 校準模體
    • 分子試劑
      • 檢體預處理試劑盒
      • 提取套件
      • 樣品製備工具包
      • 定序試劑
    • 病理耗材
      • 抗體
      • 探測
      • 染料
      • 幻燈片和錄音帶
      • 固定劑
  • 服務
    • 醫學影像服務
      • 放射影像判讀服務
      • 高級影像量化服務
    • 病理檢查
  • 軟體分析
    • 影像分析
    • 基因組分析
    • 病理資訊學

第8章：腦腫瘤診斷市場：依腫瘤類型分類

  • 原發性腦腫瘤
    • 良性
      • 脊索瘤
      • 頸靜脈球瘤
      • 腦膜瘤
      • 腦下垂體腺瘤
    • 惡性
      • 髓母細胞瘤
      • 星狀細胞瘤
      • 多形性膠質母細胞瘤
  • 次發性腫瘤

第9章：腦腫瘤診斷市場：依樣本類型分類

  • 組織樣本
  • 生物體液樣本
    • 血液檢體
    • 腦脊髓液檢體

第10章：腦腫瘤診斷市場：依腫瘤惡性度分級分類

  • 四級
  • 三年級
  • 二級
  • 一級

第11章：腦腫瘤診斷市場：依臨床應用分類

  • 診斷和表徵
    • 初步檢測
    • 鑑別診斷
    • 治療前評估
      • 術前腫瘤定位
      • 手術計劃
      • 放射治療計劃
  • 分子和病理學檢查
    • 分類和亞型分類
    • 惡性腫瘤分類與預後
    • 治療方案
  • 監測和復發評估
    • 監測治療效果
    • 監測和後續行動
    • 疾病進展追蹤

第12章：腦腫瘤診斷市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 診斷檢測實驗室
  • 學術研究機構

第13章：腦腫瘤診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：腦腫瘤診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦腫瘤診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips NV
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Bayer AG
  • Fujifilm Holdings Corporation
  • QIAGEN NV
  • Bracco Group
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Laboratory Corporation of America Holdings
  • Guerbet Laboratories Limited
  • Caris Life Sciences
  • Brainlab SE
  • Bio-Techne Corporation
  • NeoGenomics Laboratories, Inc.
  • Carl Zeiss Meditec AG
  • Bruker Corporation
  • Hamamatsu Photonics KK
  • 10x Genomics, Inc.
  • Medtronic plc
  • Biocartis NV
  • Elekta AB
  • Esaote SpA
  • Gencurix, Inc.
  • Henry Ford Health
  • Hitachi High-Tech Corporation
  • MDxHealth
  • NantOmics, LLC
  • Novocure GmbH
  • Oncologica Limited
  • Quanterix Corporation
  • Quibim, SL
  • Servier Pharmaceuticals
  • Shimadzu Corporation
  • Telix Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market is projected to grow by USD 4.03 billion at a CAGR of 10.62% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.99 billion
Estimated Year [2026] USD 2.19 billion
Forecast Year [2032] USD 4.03 billion
CAGR (%) 10.62%

Brain Cancer Diagnostics Executive Summary

Brain cancer diagnostics is moving from a primarily anatomy-based discipline to an integrated diagnostic model combining MRI, histopathology, immunohistochemistry, molecular pathology, next-generation sequencing, and increasingly liquid biopsy research. The World Health Organization's CNS tumor classification emphasizes molecular features such as IDH mutation status, 1p/19q codeletion, H3 K27 alteration, TERT promoter mutation, ATRX loss, and MGMT promoter methylation, making precision diagnostics central to treatment selection, prognosis, and clinical trial eligibility.

The clinical need is substantial. GLOBOCAN 2022 estimates about 322,000 new brain and central nervous system cancer cases and approximately 248,000 deaths worldwide, underscoring the urgency for earlier detection, accurate tumor grading, and faster molecular turnaround. For hospitals, diagnostic laboratories, imaging centers, and technology vendors, the brain cancer diagnostics landscape is increasingly defined by workflow integration, evidence-based biomarker testing, quality-assured imaging, and multidisciplinary tumor-board adoption.

Transformative Shifts in the Diagnostic Landscape

The brain cancer diagnostics landscape is being reshaped by three connected shifts: molecular classification, digital workflow adoption, and demand for minimally invasive monitoring. Conventional MRI remains foundational for detection, surgical planning, and treatment response assessment, but advanced MRI techniques, amino-acid PET in selected settings, perfusion imaging, spectroscopy, and integrated radiology-pathology review are improving diagnostic confidence.

Pathology is also changing. The WHO framework has made molecular testing indispensable rather than optional, particularly for adult diffuse gliomas and pediatric high-grade gliomas. This shift is increasing demand for validated NGS panels, methylation profiling in complex cases, robust tissue stewardship, and standardized reporting aligned with clinical guidelines. At the same time, cerebrospinal fluid and plasma-based liquid biopsy approaches are gaining research momentum for tumors where tissue access is limited, although clinical deployment still depends on analytical validation, regulatory acceptance, and demonstrated patient benefit.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across imaging triage, segmentation, radiomics, pathology image analysis, molecular prediction, and clinical decision support. AI tools can support reproducible tumor volume measurement, identify subtle imaging patterns, assist treatment response evaluation, and reduce repetitive manual workload; however, clinical value depends on external validation, explainability, bias monitoring, and integration with radiologist and pathologist workflows.

In brain cancer diagnostics, AI is most credible when positioned as an assistive layer rather than an autonomous substitute for expert interpretation. Data-backed implementation requires diverse training datasets, prospective performance monitoring, cybersecurity controls, and governance under medical device regulations. Organizations that combine AI with standardized MRI protocols, structured pathology data, and genomic results are better positioned to improve turnaround time, multidisciplinary coordination, biomarker interpretation, and eligibility screening for targeted therapies and clinical trials.

Key Regional Insights

North America remains a leading region for brain cancer diagnostics because of high MRI availability, broad adoption of molecular pathology, strong academic cancer centers, and established reimbursement pathways for clinically justified genomic testing. The United States and Canada benefit from active clinical trial networks, neuro-oncology subspecialization, and guideline-driven oncology care, although rural access, insurance complexity, and out-of-pocket costs continue to affect diagnostic equity.

Europe is shaped by centralized cancer networks, national health technology assessment, and the European Union's regulatory emphasis on in vitro diagnostic performance, medical device oversight, and data protection. Asia-Pacific combines world-class diagnostic capacity in Japan, South Korea, Australia, China's major urban centers, and Singapore with uneven access across lower-resource settings; rising neuro-oncology investment, expanding sequencing infrastructure, and digital imaging adoption are key growth drivers. Latin America is seeing increasing demand for MRI, pathology modernization, and referral-based molecular testing, led by larger urban health systems in Brazil and Mexico, while affordability and public-sector capacity remain persistent barriers. The Middle East is advancing through tertiary care investment, national cancer strategies, and international care partnerships, particularly in GCC health systems. Africa faces the greatest infrastructure constraints, including limited MRI availability, shortages of neuropathology specialists, and delayed diagnosis, yet regional referral centers and telepathology initiatives are gradually improving access to brain cancer diagnostics.

Key Group Insights

Across the G7, brain cancer diagnostics adoption is supported by mature imaging infrastructure, specialist neuro-oncology centers, recognized clinical guidelines, and reimbursement systems that increasingly treat molecular markers as clinically necessary. NATO countries overlap with many high-income health systems, supporting cross-border research collaboration, cybersecurity requirements for health data, and harmonized procurement standards for advanced diagnostic platforms.

The European Union is influential through regulatory frameworks for medical devices, in vitro diagnostics, and health data governance, creating higher evidence thresholds for diagnostic innovators while encouraging standardized quality systems. BRICS countries are strategically important because China, India, and Brazil combine large patient populations with expanding genomics and hospital investments, while Russia and South Africa contribute regional referral capacity and specialist expertise. ASEAN markets vary widely, with Singapore and Malaysia advancing precision oncology and digital pathology adoption, while other member states continue prioritizing MRI access, neuropathology training, and affordable molecular testing. GCC countries are investing in tertiary care, medical tourism, oncology centers, and national cancer strategies that favor advanced imaging, reference laboratory partnerships, and molecular testing adoption.

Key Country Insights

The United States anchors innovation through comprehensive cancer centers, regulated diagnostics, broad clinical trial activity, and high use of MRI and molecular profiling. Canada emphasizes publicly funded care, regional cancer programs, and quality-assured pathology networks, while Mexico and Brazil are expanding oncology infrastructure but face access disparities between private and public systems. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine guideline-based care with national reimbursement review, established neuro-oncology services, and increasing use of molecular classification, while Russia maintains strong urban specialist centers amid regional variation in access.

China is scaling hospital-based sequencing, AI imaging research, and tertiary neuro-oncology services, particularly in major metropolitan hospitals; India is growing rapidly in private diagnostics and oncology networks while addressing affordability, specialist distribution, and geographic access. Japan and South Korea offer advanced imaging, pathology quality, and digital health capacity, supported by aging populations, clinical research activity, and strong medical technology ecosystems. Australia benefits from integrated cancer registries, clinical trial participation, high-standard pathology networks, and advanced imaging access, making it an important precision neuro-oncology market with strong alignment to evidence-based diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, workflow-ready diagnostic solutions rather than standalone technologies. The strongest opportunities are in integrated platforms that connect MRI, pathology, genomic testing, methylation analysis, structured reporting, and tumor-board decision support while reducing turnaround time and preserving tissue for essential assays.

Vendors and providers should invest in evidence generation, including multi-center validation, analytical performance studies, health economic analysis, and real-world performance monitoring. Partnerships with academic hospitals, reference laboratories, clinical trial networks, and patient advocacy groups can accelerate adoption. Leaders should also design for interoperability, cybersecurity, regulatory compliance, and equitable access, because payers and health systems increasingly expect measurable clinical utility, reproducibility, and operational value, not only technical performance.

Research Methodology

This executive summary is developed from publicly available and verifiable sources, including WHO CNS tumor classification principles, IARC/GLOBOCAN cancer burden estimates, national cancer institute materials, peer-reviewed neuro-oncology literature, regulatory guidance, and recognized clinical practice guidelines. The analysis emphasizes diagnostic technologies with established or emerging clinical relevance, including MRI, histopathology, immunohistochemistry, molecular profiling, NGS, methylation analysis, digital pathology, AI-enabled imaging support, and liquid biopsy research.

The methodology uses triangulation across epidemiology, clinical guidelines, technology adoption patterns, regulatory considerations, regional healthcare infrastructure, and documented clinical workflow requirements. Insights are presented qualitatively where reliable comparable market figures are not publicly standardized, avoiding unsupported numerical claims. The focus is on evidence-backed strategic implications for stakeholders operating in brain cancer diagnostics.

Conclusion

Brain cancer diagnostics is entering a precision-driven phase where accurate classification, molecular confirmation, and rapid multidisciplinary interpretation directly influence therapy selection, trial eligibility, and patient counseling. The burden of CNS cancers and the complexity of glioma biology make diagnostic quality a strategic priority for health systems, laboratories, imaging providers, and technology developers.

Sustainable progress will depend on validated biomarkers, scalable molecular testing, AI-enabled workflow efficiency, regulatory-grade evidence, and equitable access to advanced imaging and pathology. Organizations that combine scientific rigor with practical implementation will be best positioned to lead in the evolving brain cancer diagnostics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
      • 4.3.1.1. Molecular Classification Is Expanding the Diagnostic Revenue Pool
      • 4.3.1.2. Advanced Imaging and Quantification Are Raising Clinical Confidence
      • 4.3.1.3. Recurring Monitoring Needs Are Turning Diagnostics Into Longitudinal Care Infrastructure
      • 4.3.1.4. Workforce Constraints Are Accelerating Automation and Outsourced Expertise
    • 4.3.2. Key Restraints
      • 4.3.2.1. Capital Intensity and Reimbursement Variability Limit Broad Adoption
      • 4.3.2.2. Regulatory Complexity Raises the Cost and Time to Commercialization
    • 4.3.3. Key Opportunities
      • 4.3.3.1. Commercializing Biofluid-Based Monitoring for Less Invasive Disease Tracking
      • 4.3.3.2. Building Multimodal Diagnostic Orchestration Platforms
      • 4.3.3.3. Scaling Regional Neuro-Oncology Diagnostic Networks
    • 4.3.4. Key Challenges
      • 4.3.4.1. Solving Fragmented Data Infrastructure Before AI Can Scale Reliably
      • 4.3.4.2. Managing Geopolitical Supply Risk Across Imaging, Reagents, and Digital Infrastructure
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Cancer Diagnostics Market, by Offering

  • 7.1. Instruments
    • 7.1.1. Imaging Instruments
      • 7.1.1.1. Magnetic Resonance Imaging (MRI) Systems
      • 7.1.1.2. Computed Tomography (CT) Scan Systems
      • 7.1.1.3. Positron Emission Tomography (PET) Systems
    • 7.1.2. Molecular & Pathology Instruments
      • 7.1.2.1. Sequencers
      • 7.1.2.2. Polymerase Chain Reaction (PCR) Systems
      • 7.1.2.3. Microarray Systems
      • 7.1.2.4. Fluorescence In Situ Hybridization (FISH) Platforms
      • 7.1.2.5. Next-Generation Sequencing (NGS) Systems
    • 7.1.3. Tissue Acquisition Instruments
      • 7.1.3.1. Biopsy Needles
      • 7.1.3.2. Stereotactic Frames
      • 7.1.3.3. Neuronavigation Systems
      • 7.1.3.4. Endoscopic Sampling Devices
  • 7.2. Consumables & Reagents
    • 7.2.1. Imaging Consumables
      • 7.2.1.1. Contrast Agents
      • 7.2.1.2. Radiotracers
      • 7.2.1.3. Calibration Phantoms
    • 7.2.2. Molecular Reagents
      • 7.2.2.1. Sample Preparation Kits
      • 7.2.2.2. Extraction Kits
      • 7.2.2.3. Library Preparation Kits
      • 7.2.2.4. Sequencing Reagents
    • 7.2.3. Pathology Consumables
      • 7.2.3.1. Antibodies
      • 7.2.3.2. Probes
      • 7.2.3.3. Stains
      • 7.2.3.4. Slides & Cassettes
      • 7.2.3.5. Fixatives
  • 7.3. Services
    • 7.3.1. Imaging Services
      • 7.3.1.1. Radiology Reading Services
      • 7.3.1.2. Advanced Imaging Quantification Services
    • 7.3.2. Pathology
  • 7.4. Software & Analytics
    • 7.4.1. Imaging Analytics
    • 7.4.2. Genomic Analytics
    • 7.4.3. Pathology Informatics

8. Brain Cancer Diagnostics Market, by Tumor Type

  • 8.1. Primary Brain Tumors
    • 8.1.1. Benign
      • 8.1.1.1. Chordomas
      • 8.1.1.2. Glomus Jugulare
      • 8.1.1.3. Meningiomas
      • 8.1.1.4. Pituitary Adenomas
    • 8.1.2. Malignant
      • 8.1.2.1. Medulloblastomas
      • 8.1.2.2. Astrocytomas
      • 8.1.2.3. Glioblastomas multiforme
  • 8.2. Secondary Brain Tumors

9. Brain Cancer Diagnostics Market, by Sample Type

  • 9.1. Tissue Samples
  • 9.2. Biofluid Samples
    • 9.2.1. Blood Samples
    • 9.2.2. Cerebrospinal Fluid Samples

10. Brain Cancer Diagnostics Market, by Tumor Grade Type

  • 10.1. Grade IV
  • 10.2. Grade III
  • 10.3. Grade II
  • 10.4. Grade I

11. Brain Cancer Diagnostics Market, by Clinical Application

  • 11.1. Diagnosis & Characterization
    • 11.1.1. Initial Detection
    • 11.1.2. Differential Diagnosis
    • 11.1.3. Pre-Treatment Assessment
      • 11.1.3.1. Preoperative Tumor Mapping
      • 11.1.3.2. Surgical Planning
      • 11.1.3.3. Radiation Planning
  • 11.2. Molecular & Pathologic Workup
    • 11.2.1. Classification & Subtyping
    • 11.2.2. Grading & Prognosis
    • 11.2.3. Treatment Selection
  • 11.3. Monitoring & Recurrence Assessment
    • 11.3.1. Response Monitoring
    • 11.3.2. Surveillance & Follow-Up
    • 11.3.3. Disease Tracking

12. Brain Cancer Diagnostics Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Diagnistics Laboratories
  • 12.4. Academic & Research Institutes

13. Brain Cancer Diagnostics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Brain Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Siemens Healthineers AG
  • 17.2. GE HealthCare Technologies Inc.
  • 17.3. Koninklijke Philips N.V.
  • 17.4. Canon Medical Systems Corporation
  • 17.5. F. Hoffmann-La Roche AG
  • 17.6. Thermo Fisher Scientific, Inc.
  • 17.7. Illumina, Inc.
  • 17.8. Danaher Corporation
  • 17.9. Bayer AG
  • 17.10. Fujifilm Holdings Corporation
  • 17.11. QIAGEN N.V.
  • 17.12. Bracco Group
  • 17.13. Shanghai United Imaging Healthcare Co., Ltd.
  • 17.14. Laboratory Corporation of America Holdings
  • 17.15. Guerbet Laboratories Limited
  • 17.16. Caris Life Sciences
  • 17.17. Brainlab SE
  • 17.18. Bio-Techne Corporation
  • 17.19. NeoGenomics Laboratories, Inc.
  • 17.20. Carl Zeiss Meditec AG
  • 17.21. Bruker Corporation
  • 17.22. Hamamatsu Photonics K.K.
  • 17.23. 10x Genomics, Inc.
  • 17.24. Medtronic plc
  • 17.25. Biocartis NV
  • 17.26. Elekta AB
  • 17.27. Esaote S.p.A.
  • 17.28. Gencurix, Inc.
  • 17.29. Henry Ford Health
  • 17.30. Hitachi High-Tech Corporation
  • 17.31. MDxHealth
  • 17.32. NantOmics, LLC
  • 17.33. Novocure GmbH
  • 17.34. Oncologica Limited
  • 17.35. Quanterix Corporation
  • 17.36. Quibim, S.L.
  • 17.37. Servier Pharmaceuticals
  • 17.38. Shimadzu Corporation
  • 17.39. Telix Pharmaceuticals Limited
  • 17.40. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTED TOMOGRAPHY (CT) SCAN SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR & PATHOLOGY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POLYMERASE CHAIN REACTION (PCR) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROARRAY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION SEQUENCING (NGS) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TISSUE ACQUISITION INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STEREOTACTIC FRAMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURONAVIGATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC SAMPLING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMAGING CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRAST AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRAST AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIOTRACERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOTRACERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIOTRACERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CALIBRATION PHANTOMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SAMPLE PREPARATION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EXTRACTION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EXTRACTION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EXTRACTION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATHOLOGY CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROBES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROBES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROBES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STAINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STAINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STAINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SLIDES & CASSETTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FIXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FIXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FIXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMAGING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMAGING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMAGING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOLOGY READING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ADVANCED IMAGING QUANTIFICATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SOFTWARE & ANALYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMAGING ANALYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENOMIC ANALYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATHOLOGY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRIMARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BENIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BENIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BENIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHORDOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CHORDOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHORDOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GLOMUS JUGULARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MENINGIOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MENINGIOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MENINGIOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PITUITARY ADENOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALIGNANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MALIGNANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALIGNANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MEDULLOBLASTOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ASTROCYTOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ASTROCYTOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ASTROCYTOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GLIOBLASTOMAS MULTIFORME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL SECONDARY BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL TISSUE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TISSUE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CEREBROSPINAL FLUID SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GRADE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GRADE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GRADE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GRADE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GRADE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GRADE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GRADE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GRADE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GRADE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GRADE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GRADE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GRADE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIAGNOSIS & CHARACTERIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL INITIAL DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL INITIAL DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL INITIAL DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIFFERENTIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PRE-TREATMENT ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PREOPERATIVE TUMOR MAPPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL SURGICAL PLANNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL SURGICAL PLANNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL SURGICAL PLANNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL RADIATION PLANNING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL RADIATION PLANNING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL RADIATION PLANNING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL MOLECULAR & PATHOLOGIC WORKUP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CLASSIFICATION & SUBTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL GRADING & PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL MONITORING & RECURRENCE ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL RESPONSE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL RESPONSE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL SURVEILLANCE & FOLLOW-UP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL DISEASE TRACKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL DISEASE TRACKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL DISEASE TRACKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIAGNISTICS LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 278. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 300. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 306. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 308. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 310. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2018-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2018-2032 (USD MILLION)
  • TABLE 314. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2018-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2018-2032 (USD MILLION)
  • TABLE 320. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2018-2032 (USD MILLION)
  • TABLE 322. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE ACQUISITION INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 331. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 332. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 333. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 334. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 335. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRIMARY BRAIN TUMORS, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BENIGN, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MALIGNANT, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOFLUID SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR GRADE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS & CHARACTERIZATION, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRE-TREATMENT ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR & PATHOLOGIC WORKUP, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & RECURRENCE ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 352. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 353. MIDDLE EAST BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, 2018-2032